Latest Breaking News On - Prnewswire biotheus inc - Page 1 : comparemela.com

Biotheus Enters Into Strategic Partnership with BioNTech to Develop and Commercialize Bispecific Antibody Candidate Targeting PD-L1 and VEGF in Multiple Solid Tumor Indications

Biotheus Enters Into Strategic Partnership with BioNTech to Develop and Commercialize Bispecific Antibody Candidate Targeting PD-L1 and VEGF in Multiple Solid Tumor Indications
kptv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kptv.com Daily Mail and Mail on Sunday newspapers.

Fosun pharmaJun baoXiaolin liuRoche groupPrnewswire biotheus incGoby globalBiotheus incBispecific antibody candidateGreater chinaAntitrust improvements actNew technologiesDuality biologics

Biotheus has entered into a license and collaboration agreement with Hansoh Pharma for its EGFR/MET bispecific antibody in the Greater China territory

ZHUHAI, China, Nov. 14, 2022 /PRNewswire/ Biotheus Inc., a clinical-stage biotech company focused on the discovery and development of biologics.

United statesHong kongMacau generalAlmonertinib ameileFlumatinib xinfuTenofovir amibufenamideInebilizumab xinyueXiaolin liuMorinidazole mailingdaYun sunHansoh pharmaHansoh pharmaceuticalsPrnewswire biotheus incBiotheus incGreater chinaMainland china

Biotheus Bifunctional Therapeutic PM8001 has been Approved by the USFDA to Enter Phase II Studies

/PRNewswire/ Biotheus Inc., has announced that its proprietary anti-PD-L1/TGF-β bifunctional therapeutic, named PM8001, has been approved by the USFDA.

United statesLiu xiaolinDrug administrationPrnewswire biotheus incBiotheus incUnited states foodBiotheus inc

Biotheus Bifunctional Therapeutic PM8001 has been Approved by the USFDA to Enter Phase II Studies

/PRNewswire/ Biotheus Inc., has announced that its proprietary anti-PD-L1/TGF-β bifunctional therapeutic, named PM8001, has been approved by the USFDA.

United statesLiu xiaolinDrug administrationPrnewswire biotheus incBiotheus incUnited states foodBiotheus inc

Latest Breaking News On - Prnewswire biotheus inc - Page 1 : comparemela.com

Biotheus Enters Into Strategic Partnership with BioNTech to Develop and Commercialize Bispecific Antibody Candidate Targeting PD-L1 and VEGF in Multiple Solid Tumor Indications

Biotheus has entered into a license and collaboration agreement with Hansoh Pharma for its EGFR/MET bispecific antibody in the Greater China territory

Biotheus Bifunctional Therapeutic PM8001 has been Approved by the USFDA to Enter Phase II Studies

/PRNewswire/ Biotheus Inc., has announced that its proprietary anti-PD-L1/TGF-β bifunctional therapeutic, named PM8001, has been approved by the USFDA.United statesLiu xiaolinDrug administrationPrnewswire biotheus incBiotheus incUnited states foodBiotheus inc

Biotheus Bifunctional Therapeutic PM8001 has been Approved by the USFDA to Enter Phase II Studies

/PRNewswire/ Biotheus Inc., has announced that its proprietary anti-PD-L1/TGF-β bifunctional therapeutic, named PM8001, has been approved by the USFDA.United statesLiu xiaolinDrug administrationPrnewswire biotheus incBiotheus incUnited states foodBiotheus inc

/PRNewswire/ Biotheus Inc., has announced that its proprietary anti-PD-L1/TGF-β bifunctional therapeutic, named PM8001, has been approved by the USFDA.

United statesLiu xiaolinDrug administrationPrnewswire biotheus incBiotheus incUnited states foodBiotheus inc

/PRNewswire/ Biotheus Inc., has announced that its proprietary anti-PD-L1/TGF-β bifunctional therapeutic, named PM8001, has been approved by the USFDA.

United statesLiu xiaolinDrug administrationPrnewswire biotheus incBiotheus incUnited states foodBiotheus inc